TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 32725991

Group type: EXPERIMENTAL
Intervention: Low CFR (≤2) in high FFR group
Number of subjects: 867

Group type: EXPERIMENTAL
Intervention: Low CFR (≤2) in low FFR group
Number of subjects: 867

Group type: EXPERIMENTAL
Intervention: Low CFR (≤2) and high IMR (≥23 U) in high FFR group
Number of subjects: 867

Group type: EXPERIMENTAL
Intervention: Overt microvascular disease in high FFR group
Number of subjects: 867
Study: 32726419

Group type: EXPERIMENTAL
Intervention: Maribavir (400-1200 mg twice daily)
Number of subjects: 239
Study: 32726447

Group type: EXPERIMENTAL
Intervention: Mealtime Engagement Scale (MES)
Number of subjects: 18
Study: 32726554

Group type: EXPERIMENTAL
Intervention: Clobetasol propionate 0.05% emollient foam applied daily
Number of subjects: 30
Study: 32726560

Group type: EXPERIMENTAL
Intervention: Leptin levels in cord blood
Number of subjects: 0
Study: 32726602

Group type: EXPERIMENTAL
Intervention: Deferiprone (anti-ferroptotic iron chelator)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ongoing larger multi-centre phase 2 clinical trial of deferiprone
Number of subjects: 0
Study: 32727600

Group type: EXPERIMENTAL
Intervention: Natural History Study (NHS) of FOP
Number of subjects: 114

Group type: EXPERIMENTAL
Intervention: Echocardiograms from 22 patients with FOP
Number of subjects: 114
Study: 32727853

Group type: COMPARATOR
Intervention: Primary microvascular angina (MVA)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Takotsubo syndrome (TTS)
Number of subjects: 50
Study: 32728218

Group type: EXPERIMENTAL
Intervention: RNA vaccine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Checkpoint inhibitor treatment
Number of subjects: 0
Study: 32728595

Group type: EXPERIMENTAL
Intervention: AZD8601 (synthetic mRNA encoding VEGF-A)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 32728832

Group type: COMPARATOR
Intervention: Mealtime ultra-rapid lispro (URLi)
Number of subjects: 167

Group type: COMPARATOR
Intervention: Postmeal ultra-rapid lispro (URLi)
Number of subjects: 167

Group type: EXPERIMENTAL
Intervention: Mealtime and postmeal ultra-rapid lispro (URLi)
Number of subjects: 167
Study: 32728833

Group type: EXPERIMENTAL
Intervention: Ultra-rapid lispro (URLi)
Number of subjects: 93

Group type: COMPARATOR
Intervention: Lispro
Number of subjects: 93
Study: 32728839

Group type: EXPERIMENTAL
Intervention: Social jet lag (SJL)
Number of subjects: 122
Study: 32728880

Group type: EXPERIMENTAL
Intervention: Maternal diet (fat intake: saturated fatty acids (SFA) and monounsaturated fatty acids (MUFA))
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: Maternal intestinal markers (zonulin, intestinal alkaline phosphatase activity, faecal calprotectin)
Number of subjects: 73
Study: 32728965

Group type: EXPERIMENTAL
Intervention: Invasive mechanical ventilation (MV)
Number of subjects: 742
Study: 32729929

Group type: EXPERIMENTAL
Intervention: Nivolumab at 3 mg/kg and Ipilimumab at 1 mg/kg every 3 weeks for 4 doses, followed by Nivolumab 3 mg/kg every 2 weeks for up to 96 weeks.
Number of subjects: 39
Study: 32730119

Group type: EXPERIMENTAL
Intervention: Pneumococcal conjugate vaccine (PCV) - 4 doses
Number of subjects: 825

Group type: EXPERIMENTAL
Intervention: Mixed PCV10 + PCV13 schedule
Number of subjects: 825

Group type: COMPARATOR
Intervention: Unvaccinated children
Number of subjects: 825
Study: 32730186

Group type: EXPERIMENTAL
Intervention: Pembrolizumab (200 mg every 3 weeks)
Number of subjects: 39
Study: 32730187

Group type: EXPERIMENTAL
Intervention: Allogeneic stem cell transplantation (SCT) after reinduction chemotherapy for very high risk and high risk patients.
Number of subjects: 116

Group type: EXPERIMENTAL
Intervention: Vinblastine monotherapy for low risk patients (CD3-negative relapse > 1 year after initial diagnosis).
Number of subjects: 116

Group type: EXPERIMENTAL
Intervention: Vinblastine monotherapy for intermediate risk patients after termination of autologous SCT.
Number of subjects: 116

Group type: EXPERIMENTAL
Intervention: Autologous SCT for intermediate risk patients (prior to termination).
Number of subjects: 116

Group type: EXPERIMENTAL
Intervention: Vinblastine monotherapy for early relapses.
Number of subjects: 116

Group type: EXPERIMENTAL
Intervention: Autologous SCT for early relapses.
Number of subjects: 116

Group type: EXPERIMENTAL
Intervention: Allogeneic SCT for high-risk ALCL relapse.
Number of subjects: 116
Study: 32730305

Group type: EXPERIMENTAL
Intervention: Nutritional status (measured by mini-nutritional assessment scale, total protein levels, CRP)
Number of subjects: 113

Group type: EXPERIMENTAL
Intervention: Protein-energy wasting
Number of subjects: 113

Group type: EXPERIMENTAL
Intervention: Nutritional status
Number of subjects: 113
Study: 32730586

Group type: EXPERIMENTAL
Intervention: AFM13 in combination with pembrolizumab
Number of subjects: 0

Group type: COMPARATOR
Intervention: AFM13
Number of subjects: 0

Group type: COMPARATOR
Intervention: pembrolizumab
Number of subjects: 0
Study: 32730756

Group type: EXPERIMENTAL
Intervention: HIV-positive to HIV-positive kidney and liver transplantation
Number of subjects: 22
Study: 32731102

Group type: EXPERIMENTAL
Intervention: Core body temperature (CBT) measurements in patients with sepsis (n=12)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Core body temperature (CBT) measurements in patients without sepsis
Number of subjects: 33
Study: 32731841

Group type: EXPERIMENTAL
Intervention: Colon capsule endoscopy (CCE)
Number of subjects: 97

Group type: COMPARATOR
Intervention: Computed tomography colonography (CTC)
Number of subjects: 97
Study: 32732023

Group type: EXPERIMENTAL
Intervention: Hypophosphataemia (phosphataemia below 0.8 mmol/L)
Number of subjects: 193

Group type: COMPARATOR
Intervention: Patients without hypophosphataemia
Number of subjects: 193
Study: 32732224

Group type: EXPERIMENTAL
Intervention: Vaccination targeting HER2Δ16
Number of subjects: 0

Group type: COMPARATOR
Intervention: Vaccines targeting a nondriver tumor-specific antigen or tumor neoepitopes
Number of subjects: 0
Study: 32732303

Group type: EXPERIMENTAL
Intervention: ADNEX with CA125
Number of subjects: 5717

Group type: EXPERIMENTAL
Intervention: ADNEX without CA125
Number of subjects: 5717

Group type: EXPERIMENTAL
Intervention: SRRisk
Number of subjects: 5717

Group type: EXPERIMENTAL
Intervention: RMI
Number of subjects: 5717

Group type: EXPERIMENTAL
Intervention: ADNEX models and SRRisk
Number of subjects: 5717
Study: 32732318

Group type: EXPERIMENTAL
Intervention: Children with CHD
Number of subjects: 709

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 709
Study: 32732355

Group type: EXPERIMENTAL
Intervention: Axicabtagene ciloleucel
Number of subjects: 31
Study: 32732380

Group type: EXPERIMENTAL
Intervention: Delayed cord clamping (DCC) or umbilical cord milking (UCM)
Number of subjects: 3116
Study: 32733187

Group type: EXPERIMENTAL
Intervention: Non-invasive sensory feedback system
Number of subjects: 7
Study: 32733232

Group type: EXPERIMENTAL
Intervention: Real/Real group (rTMS + cognitive training)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Sham/Sham group (control)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Real/Sham group (rTMS only)
Number of subjects: 34
Study: 32733577

Group type: EXPERIMENTAL
Intervention: Standard treatments combined with acupuncture therapy (electroacupuncture and scalp acupuncture) for a median course of five months
Number of subjects: 315

Group type: EXPERIMENTAL
Intervention: Standard treatments combined with acupuncture therapy
Number of subjects: 315
Study: 32733600

Group type: EXPERIMENTAL
Intervention: Adalimumab 160/80 mg at weeks 0/2 and 40 mg at weeks 4/6
Number of subjects: 205

Group type: COMPARATOR
Intervention: Placebo at weeks 0/2 followed by adalimumab 160/80 mg at weeks 4/6
Number of subjects: 205
Study: 32733606

Group type: EXPERIMENTAL
Intervention: Intrathecal pemetrexed (IP) combined with involved-field radiotherapy (IFRT)
Number of subjects: 34
Study: 32733900

Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Mycophenolate Mofetil
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 32733902

Group type: EXPERIMENTAL
Intervention: Gut microbiota analysis in critically ill patients after cardiovascular surgery with sepsis
Number of subjects: 0

Group type: COMPARATOR
Intervention: Gut microbiota analysis in critically ill patients after cardiovascular surgery without sepsis
Number of subjects: 0
Study: 32734176

Group type: EXPERIMENTAL
Intervention: Parenteral rotavirus vaccine
Number of subjects: 0
Study: 32734200

Group type: EXPERIMENTAL
Intervention: Electronic patient decision support tool
Number of subjects: 70
Study: 32734204

Group type: EXPERIMENTAL
Intervention: CKD registry with point-of-care notifications and quarterly feedback for 12 months
Number of subjects: 137

Group type: EXPERIMENTAL
Intervention: CKD self-management support program for 12 months
Number of subjects: 137

Group type: COMPARATOR
Intervention: Usual care registry for 12 months
Number of subjects: 137

Group type: COMPARATOR
Intervention: Usual care for 12 months
Number of subjects: 137
Study: 32734207

Group type: EXPERIMENTAL
Intervention: Epoetin alfa-epbx
Number of subjects: 1425

Group type: COMPARATOR
Intervention: Epoetin alfa
Number of subjects: 1425

Group type: COMPARATOR
Intervention: Combined randomized groups (epoetin alfa-epbx and epoetin alfa)
Number of subjects: 1425

Group type: EXPERIMENTAL
Intervention: Combined long-term safety studies group
Number of subjects: 1425

Group type: COMPARATOR
Intervention: Epoetin alfa-epbx and epoetin alfa
Number of subjects: 1425
Study: 32734226

Group type: EXPERIMENTAL
Intervention: Immediate intensive nonsurgical periodontal treatment
Number of subjects: 51

Group type: COMPARATOR
Intervention: Rescue treatment for progressive disease
Number of subjects: 51
Study: 32734238

Group type: EXPERIMENTAL
Intervention: Balanced salt solution
Number of subjects: 493

Group type: COMPARATOR
Intervention: 0.9% saline solution
Number of subjects: 493
Study: 32734246

Group type: EXPERIMENTAL
Intervention: Exercise program (resistance and aerobic exercise using exercise bands) with monthly consultations and 4 support calls over 12 weeks
Number of subjects: 36

Group type: COMPARATOR
Intervention: Standard care (control group)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Exercise program (intervention group)
Number of subjects: 36
Study: 32734251

Group type: EXPERIMENTAL
Intervention: Group-based care (monthly sessions over 6 months)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Group-based care (for adolescents)
Number of subjects: 60
Study: 32734299

Group type: EXPERIMENTAL
Intervention: Panic Disorder (PD) patients who are smokers
Number of subjects: 143

Group type: EXPERIMENTAL
Intervention: Panic Disorder (PD) patients who are non-smokers
Number of subjects: 143

Group type: COMPARATOR
Intervention: Healthy controls who are smokers
Number of subjects: 143

Group type: COMPARATOR
Intervention: Healthy controls who are non-smokers
Number of subjects: 143
Study: 32734347

Group type: EXPERIMENTAL
Intervention: Organic food consumption (23.3%)
Number of subjects: 34193

Group type: EXPERIMENTAL
Intervention: Intermediate organic food consumption
Number of subjects: 34193

Group type: EXPERIMENTAL
Intervention: High conventional fruits and vegetable intake
Number of subjects: 34193

Group type: EXPERIMENTAL
Intervention: Highest organic food consumption (31.5%)
Number of subjects: 34193

Group type: EXPERIMENTAL
Intervention: Clusters with varying organic food proportions
Number of subjects: 34193
Study: 32734597

Group type: COMPARATOR
Intervention: Antidepressants
Number of subjects: 4674

Group type: COMPARATOR
Intervention: Pentosan polysulfate (PPS)
Number of subjects: 4674

Group type: COMPARATOR
Intervention: Neuromuscular blockade
Number of subjects: 4674
Study: 32734695

Group type: EXPERIMENTAL
Intervention: Omental adipose tissue (OMAT) in older women
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Omental adipose tissue (OMAT) in older men
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Subcutaneous adipose tissue (SQAT) in women
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Protein content of ER alpha and ERβ
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Subcutaneous inflammatory gene expression
Number of subjects: 71
Study: 32735048

Group type: EXPERIMENTAL
Intervention: CLL International Prognostic Index (CLL-IPI)
Number of subjects: 3307

Group type: EXPERIMENTAL
Intervention: Barcelona-Brno score
Number of subjects: 3307

Group type: EXPERIMENTAL
Intervention: MDACC 2007 index score
Number of subjects: 3307
Study: 32735111

Group type: EXPERIMENTAL
Intervention: Dietary nitrate supplementation with beetroot juice
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Sodium nitrite supplementation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Nitrate supplementation
Number of subjects: 0
Study: 32735641

Group type: EXPERIMENTAL
Intervention: Carfilzomib-lenalidomide-dexamethasone (KRd) with autologous stem cell transplantation (ASCT)
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Carfilzomib-lenalidomide-dexamethasone (KRd) with ASCT
Number of subjects: 76
Study: 32735836

Group type: EXPERIMENTAL
Intervention: Selinexor (60 mg twice per week for 2 weeks, followed by 1 week off)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Selinexor
Number of subjects: 25
Study: 32736411

Group type: EXPERIMENTAL
Intervention: Sonidegib 800 mg QD
Number of subjects: 0
Study: 32736511

Group type: EXPERIMENTAL
Intervention: ACL surgery (n=64), performed a mean of 5 days after injury
Number of subjects: 153

Group type: COMPARATOR
Intervention: No ACL surgery (n=89), with subgroups of 53 remaining nonsurgically treated, 27 having surgery within 2 years, and 9 having surgery between 3 and 21 years after injury
Number of subjects: 153

Group type: EXPERIMENTAL
Intervention: Overall sample (n=153)
Number of subjects: 153
Study: 32736543

Group type: EXPERIMENTAL
Intervention: hsRDT
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: LAMP
Number of subjects: 0

Group type: COMPARATOR
Intervention: Microscopy
Number of subjects: 0

Group type: COMPARATOR
Intervention: cRDT
Number of subjects: 0
Study: 32736788

Group type: EXPERIMENTAL
Intervention: Participatory working time scheduling software
Number of subjects: 9000

Group type: COMPARATOR
Intervention: Traditional scheduling
Number of subjects: 9000
Study: 32736826

Group type: EXPERIMENTAL
Intervention: Extracorporeal membrane oxygenation (ECMO)
Number of subjects: 1205

Group type: EXPERIMENTAL
Intervention: Increased severity of hypoxaemia at time of decision-to-cannulate
Number of subjects: 1205
Study: 32736936

Group type: EXPERIMENTAL
Intervention: Stereotactic ablative body radiotherapy (SABR)
Number of subjects: 481
Study: 32737003

Group type: EXPERIMENTAL
Intervention: FOLFOX6 with cetuximab (500 mg/m2 biweekly)
Number of subjects: 57
Study: 32737076

Group type: EXPERIMENTAL
Intervention: Proximity to parental age at onset (AAO) in sporadic Alzheimer disease (AD)
Number of subjects: 290
Study: 32737087

Group type: EXPERIMENTAL
Intervention: Monthly subcutaneous BUP-XR injections administered by a healthcare practitioner at intervals of 28 days (-2/+14 days) after a minimum of 7 days on 8-32 mg of sublingual buprenorphine (±naloxone)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Monthly subcutaneous BUP-XR injections
Number of subjects: 0
Study: 32737088

Group type: EXPERIMENTAL
Intervention: Educational intervention between prescribers and ASP leaders to reinforce proper use of novel antibiotics.
Number of subjects: 0
Study: 32737116

Group type: EXPERIMENTAL
Intervention: Relative Hypoxia
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 32737209

Group type: EXPERIMENTAL
Intervention: Oropharyngeal CT testing at week 0
Number of subjects: 560

Group type: EXPERIMENTAL
Intervention: Treatment with azithromycin or doxycycline
Number of subjects: 560

Group type: EXPERIMENTAL
Intervention: Spontaneous clearance of oropharyngeal CT
Number of subjects: 560

Group type: EXPERIMENTAL
Intervention: Follow-up visits between weeks 4 and 12
Number of subjects: 560

Group type: COMPARATOR
Intervention: Women not tested at week -1
Number of subjects: 560
Study: 32737707

Group type: EXPERIMENTAL
Intervention: Right ventricular dysfunction (RVD) defined as right ventricular ejection fraction < 47% in HFpEF patients
Number of subjects: 183

Group type: EXPERIMENTAL
Intervention: Composite endpoint of death or HF hospitalization in HFpEF patients
Number of subjects: 183

Group type: EXPERIMENTAL
Intervention: RVD as assessed by CMR
Number of subjects: 183

Group type: EXPERIMENTAL
Intervention: RVD as an independent predictor of adverse outcomes
Number of subjects: 183

Group type: EXPERIMENTAL
Intervention: Indexed extracellular volume
Number of subjects: 183

Group type: EXPERIMENTAL
Intervention: E/E' ratio
Number of subjects: 183
Study: 32737717

Group type: EXPERIMENTAL
Intervention: Cobimetinib (60 mg) and Ipatasertib (200 mg) in Arm A
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Cobimetinib (150 mg) and Ipatasertib (300 mg) in Arm B
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Combination of Cobimetinib and Ipatasertib
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Pharmacodynamic analyses
Number of subjects: 66
Study: 32738041

Group type: EXPERIMENTAL
Intervention: rhPTH(1-84) therapy
Number of subjects: 122

Group type: COMPARATOR
Intervention: Control (no rhPTH(1-84))
Number of subjects: 122
Study: 32738042

Group type: EXPERIMENTAL
Intervention: 45-mg subcutaneous leuprolide acetate (0.375 mL) at 0 and 24 weeks
Number of subjects: 64
Study: 32738255

Group type: EXPERIMENTAL
Intervention: Enzyme-based immunodetection assay (in-cell ELISA) for quantifying SARS-CoV-2 infection.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Traditional methods (staining plaques or foci, PCR) for detecting SARS-CoV-2 infection.
Number of subjects: 0
Study: 32738404

Group type: EXPERIMENTAL
Intervention: Competitive atrial pacing (CAP)
Number of subjects: 5379

Group type: EXPERIMENTAL
Intervention: CAP-triggered AT/AF
Number of subjects: 5379

Group type: COMPARATOR
Intervention: Spontaneous AT/AF
Number of subjects: 5379
Study: 32738543

Group type: EXPERIMENTAL
Intervention: PIPAC procedure training model
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: PIPAC procedure publications
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Conflict of interest in studies
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Controlled training model
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Ethical implications of industry involvement
Number of subjects: 4
Study: 32738823

Group type: EXPERIMENTAL
Intervention: Pazopanib 800 mg daily
Number of subjects: 60
Study: 32738880

Group type: EXPERIMENTAL
Intervention: Staff education programme about person-centred care and promotion of thriving (14-month duration)
Number of subjects: 0

Group type: COMPARATOR
Intervention: One-hour lecture for staff (Control)
Number of subjects: 0
Study: 32738905

Group type: EXPERIMENTAL
Intervention: Systemic arteriosclerosis assessed by carotid femoral artery pulse wave velocity (CF-PWV) > 12 m/s
Number of subjects: 1178

Group type: EXPERIMENTAL
Intervention: Multi-site atherosclerotic plaques (MAP)
Number of subjects: 1178

Group type: EXPERIMENTAL
Intervention: Peripheral artery disease
Number of subjects: 1178

Group type: EXPERIMENTAL
Intervention: Smoking
Number of subjects: 1178

Group type: EXPERIMENTAL
Intervention: CF-PWV > 12 m/s
Number of subjects: 1178

Group type: EXPERIMENTAL
Intervention: Dyslipidemia
Number of subjects: 1178

Group type: EXPERIMENTAL
Intervention: Male
Number of subjects: 1178

Group type: EXPERIMENTAL
Intervention: Stroke
Number of subjects: 1178

Group type: EXPERIMENTAL
Intervention: Hypoglycemic agents
Number of subjects: 1178

Group type: EXPERIMENTAL
Intervention: Age
Number of subjects: 1178
Study: 32738928

Group type: EXPERIMENTAL
Intervention: Inhaled corticosteroids
Number of subjects: 0
Study: 32739261

Group type: EXPERIMENTAL
Intervention: PHVD
Number of subjects: 4216

Group type: COMPARATOR
Intervention: Hemorrhage without ventricular dilatation
Number of subjects: 4216

Group type: COMPARATOR
Intervention: Normal head ultrasound
Number of subjects: 4216

Group type: EXPERIMENTAL
Intervention: Intervention for progressive dilatation
Number of subjects: 4216

Group type: COMPARATOR
Intervention: No intervention for progressive dilatation
Number of subjects: 4216
Study: 32739453

Group type: EXPERIMENTAL
Intervention: Coarctation of the aorta
Number of subjects: 3538

Group type: EXPERIMENTAL
Intervention: Isolated aortic valve disease
Number of subjects: 3538

Group type: EXPERIMENTAL
Intervention: Cyanotic heart disease
Number of subjects: 3538

Group type: EXPERIMENTAL
Intervention: Eisenmenger syndrome
Number of subjects: 3538
Study: 32739654

Group type: EXPERIMENTAL
Intervention: Saizen® administered via easypod™
Number of subjects: 86
Study: 32740083

Group type: EXPERIMENTAL
Intervention: C4 (7α-hydroxy-4-cholesten-3-one)
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: FGF19
Number of subjects: 71
Study: 32740096

Group type: EXPERIMENTAL
Intervention: Endoscopic ultrasound guided gastroenterostomy (EUS-GE)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Endoscopic ultrasound guided gastroenterostomy (EUS-GE) with misdeployed lumen-apposing metal stent
Number of subjects: 23
Study: 32740125

Group type: EXPERIMENTAL
Intervention: CMV reactivation post-LVAD implantation
Number of subjects: 349

Group type: COMPARATOR
Intervention: CMV reactivation
Number of subjects: 349
Study: 32740129

Group type: EXPERIMENTAL
Intervention: Small intrapericardial centrifugal LVAD
Number of subjects: 0

Group type: COMPARATOR
Intervention: Medical management (MM)
Number of subjects: 0
Study: 32740181

Group type: EXPERIMENTAL
Intervention: Remote telesimulation with standardized parents (90-minute Skype sessions)
Number of subjects: 79
Study: 32740184

Group type: EXPERIMENTAL
Intervention: Instantaneous newborn infant parasympathetic evaluation score
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Mean newborn infant parasympathetic evaluation score
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Comfort Behavior scores
Number of subjects: 32
Study: 32740221

Group type: EXPERIMENTAL
Intervention: Exercise Training (ET)
Number of subjects: 16
Study: 32740343

Group type: EXPERIMENTAL
Intervention: Centrifugal LVAD implantation via thoracotomy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Medical Management arm
Number of subjects: 0
Study: 32740508

Group type: EXPERIMENTAL
Intervention: Glaucoma Treatment Compliance Assessment Tool (GTCAT)
Number of subjects: 0
Study: 32740873

Group type: EXPERIMENTAL
Intervention: Fatigue Severity Scale (FSS)
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: HADS-Depression, PSQI, and ACTIVLIM
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Motor fatigability tests (6-min Walk Test and isometric muscular fatigability test)
Number of subjects: 62